Author:
Nicosia Luca,Franzese Ciro,Mazzola Rosario,Franceschini Davide,Rigo Michele,D’agostino Giuseppe,Corradini Stefanie,Alongi Filippo,Scorsetti Marta
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Radiology, Nuclear Medicine and imaging
Reference30 articles.
1. Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M (2015) Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol 68(2):325–334 (Aug)
2. Ingrosso G, Detti B, Scartoni D, Lancia A, Giacomelli I, Baki M, Carta G, Livi L, Santoni R. Current therapeutic options in metastatic castration-resistant prostate cancer. Semin Oncol. 2018 Oct 30. pii: S0093-7754(17)30050‑7.
3. Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, Brewer DS, Kallio HML, Högnäs G, Annala M, Kivinummi K, Goody V, Latimer C, O’Meara S, Dawson KJ, Isaacs W, Emmert-Buck MR, Nykter M, Foster C, Kote-Jarai Z, Easton D, Whitaker HC, ICGC Prostate Group (2015) Eeles RA, Visakorpi T, Campbell PJ, McDermott U, Wedge DC, Bova GS. The evolutionary history of lethal metastatic prostate cancer. Nature 16;520(7547):353–357 (Apr)
4. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ, Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer (2016) Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol 20;34(12):1402–1418 (Apr)
5. Palma DA, Olson RA, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy LA, Lock MI, Rodrigues G, Yaremko BP, Schellenberg D, Ahmad B, Griffioen G, Senthi S, Liu MC, Moore K, Currie S, Bauman GS, Warner A, Senan S (2018) Stereotactic Ablative Radiation Therapy for the Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET): Results of a Randomized Trial. Int J Radiol Oncol Biol Phys 102(3):S3–S4.
https://doi.org/10.1016/j.ijrobp.2018.06.105
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献